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Abstract
Objective:  Report  the  incidence,  epidemiology,  clinical  features,  death,  and  vaccination  sta-
tus of  patients  with  whooping  cough  and  perform  genotypic  characterization  of  isolates  of  B.
pertussis identiﬁed  in  the  state  of  Paraná,  during  January  2007  to  December  2013.
Methods:  Cross-sectional  study  including  1,209  patients  with  pertussis.  Data  were  obtained
through the  Notiﬁable  Diseases  Information  System  (Sistema  de  Informac¸ão  de  Agravos  de
Notiﬁcac¸ão --  SINAN)  and  molecular  epidemiology  was  performed  by  repetitive  sequence-based
polymerase  chain  reaction  (rep-PCR;  DiversiLab®,  bioMerieux,  France).
Results:  The  incidence  of  pertussis  in  the  state  of  Paraná  increased  sharply  from  0.15-0.76  per
100,000 habitants  between  2007-2010  to  1.7-4.28  per  100,000  between  2011-2013.  Patients  with
less than  1  year  of  age  were  more  stricken  (67.5%).  Fifty-nine  children  (5%)  developed  pertussis
even after  receiving  three  doses  and  two  diphtheria-tetanus-pertussis  (DTP)  boosters  vaccine.
The most  common  complications  were  pneumonia  (14.5%),  otitis  (0.9%),  and  encephalopathy
(0.7%).  Isolates  of  B.  pertussis  were  grouped  into  two  groups  (G1  and  G2)  and  eight  distinct
patterns (G1:  P1-P5  and  G2:  P6-P8).
Conclusion:  The  resurgence  of  pertussis  should  stimulate  new  research  to  develop  vaccines
with greater  capacity  of  protection  against  current  clones  and  also  encourage  implementation
of new  strategies  for  vaccination  in  order  to  reduce  the  risk  of  disease  in  infants.
© 2015  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.
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Ressurgimento  da  coqueluche  na  era  vacinal:  aspectos  clínicos,  epidemiológicos  e
moleculares
Resumo
Objetivo:  Relatar  a  incidência,  aspectos  epidemiológicos,  clínicos,  morte  e  a  vacinac¸ão  de
pacientes com  coqueluche  e  realizar  a  caracterizac¸ão  genotípica  de  isolados  de  B.  pertussis
identiﬁcados  no  estado  do  Paraná,  de  janeiro  de  2007  a  dezembro  de  2013.
Métodos: Estudo  transversal,  incluindo  1.209  pacientes  com  coqueluche.  Os  dados  foram  obti-
dos através  do  Sistema  de  Informac¸ão  de  Agravos  de  Notiﬁcac¸ão  (SINAN)  e  a  epidemiologia
molecular foi  realizada  por  PCR  baseada  em  sequências  repetitivas  (rep-PCR;  DiversiLab®,
bioMerieux,  France).
Resultados:  A  incidência  de  coqueluche  no  Estado  do  Paraná  aumentou  acentuadamente  de
0,15-0,76 por  100.000  habitantes  entre  2007-2010  para  1,7-4,28  por  100.000  habitantes  entre
2011-2013. Os  pacientes  com  menos  de  um  ano  de  idade  foram  os  mais  afetados  (67,5%).  Cin-
quenta e  nove  crianc¸as  (5%)  desenvolveram  coqueluche  mesmo  depois  de  receber  três  doses  da
vacina e  dois  reforc¸os  com  a  vacina  tríplice  DTP.  As  complicac¸ões  mais  comuns  foram  pneumonia
(14,5%), otite  (0,9%)  e  encefalopatia  (0,7%).  Isolados  de  B.  pertussis  foram  agrupados  em  dois
grupos (G1  e  G2)  e  oito  padrões  distintos  (G1:  P1-P5  e  G2:  P6-P8).
Conclusão:  O  ressurgimento  da  coqueluche  vem  para  sugerir  novas  pesquisas  com  o  objetivo
se desenvolver  vacinas  com  maior  capacidade  de  protec¸ão  contra  os  clones  atuais  e  também
implementar  novas  estratégias  de  vacinac¸ão,  a  ﬁm  de  reduzir  o  risco  de  doenc¸as  em  lactentes.
© 2015  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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ertussis,  commonly  known  as  whooping  cough,  is  a  severe,
ighly  contagious  disease  of  the  human  respiratory  tract,
aused  by  Bordetella  pertussis.1 The  disease  is  charac-
erized  by  uncontrollable  coughing  ﬁts,  accompanied  by
nspiratory  stridor.2 Children  and  adults  of  any  age  can
evelop  the  disease;  however,  it  is  more  severe  in  infants,
specially  up  to  6  months  of  age.3 Despite  good  vaccination
overage,  it  is  estimated  that  50  million  cases  occur  each
ear,  with  approximately  300,000  deaths  annually,  90%  of
hem  in  developing  countries.1,4
The  last  decade  showed  a  surprising  increase  in  inci-
ence  rates  of  pertussis  in  several  regions  of  the  world.
he  causes  of  this  disease  resurgence  are  still  unclear.  Some
ypotheses  raised  were  post-vaccine  immunity  loss;  imple-
entation  of  molecular  methods  for  diagnosis;  improvement
f  epidemiological  surveillance  systems;  reduction  of
he  vaccine  efﬁcacy;  or  even  genetic  changes  in  the
athogen.5,6
In  Brazil,  pertussis  was  included  in  the  notiﬁable  dis-
ases  list  in  1975,  with  the  recommendation  to  investigate
ll  disease  outbreaks.  In  the  early  1980s,  there  were
ore  than  40,000  cases  a  year  and  the  incidence  rate
as  >  30/100,000  inhabitants.  This  number  has  decreased
harply  since  1983,  with  the  introduction  of  the  diphtheria-
etanus-pertussis  (DTP)  vaccine  in  the  Brazilian  childhood
accination  schedule;  since  then,  it  has  shown  a  downward
rend.  Evidence  of  pertussis  resurgence  in  Brazil  was  demon-
trated  by  the  detection  of  some  outbreaks  in  2010,  followed
y  an  increase  in  the  number  of  cases  in  several  Brazilian
apitals.7
o
a
B
JThe  monitoring  of  B.  pertussis  circulation  is  being  per-
ormed  in  the  Brazilian  states,  with  the  implementation  of
urveillance  services  and  qualiﬁed  laboratories  for  the  iso-
ation  of  the  etiological  agent.  The  methods  used  in  the
aboratory  diagnosis  of  pertussis  include  culture  and  real
ime  polymerase  chain  reaction  (RT-PCR).  The  diagnosis  of
ertussis  by  laboratory  testing  was  implemented  in  the  Cen-
ral  Laboratory  of  the  state  of  Paraná  (Lacen-PR)  in  2005.
he  test  (culture)  was  ﬁrst  made  available  for  three  sentinel
ospitals;  two  implemented  in  the  capital  city  of  Curitiba
nd  another  in  the  city  of  Londrina.
The  ﬁrst  isolation  of  B.  pertussis  occurred  only  in  2007,  in
 family  contact  with  cough,  from  a  child  with  the  disease
ymptoms.  In  2011,  the  survey  was  expanded  to  all  Basic
ealth  Units  (BHUs)  and  other  hospitals  in  the  city  of  Curitiba
nd  the  metropolitan  area.  These  services  received  training
hat  addressed  clinical  diagnosis,  epidemiological  behav-
or,  and  biological  sample  collection.  Recently,  some  studies
ave  reported  the  use  of  repetitive  element  sequence-
ased  PCR  (rep-PCR;  DiversiLab®,  bioMerieux,  France)  for
olecular  typing  of  microorganisms.  This  method  uses
ligonucleotide  primers  complementary  to  repetitive  highly
onserved  DNA  sequences  present  at  numerous  copies  in
he  bacterial  genome.  It  allows  genotypic  characteriza-
ion,  clone  differentiation,  and  their  dispersion  in  the
ommunity.8
The  objective  of  this  study  was  to  describe  the  inci-
ence,  epidemiological  and  clinical  characteristics,  number
f  deaths  and  vaccination  status,  of  patients  with  pertussis,
nd  to  perform  the  genotypic  characterization  of  isolates  of
.  pertussis  circulating  in  the  state  of  Paraná,  Brazil,  from
anuary  of  2007  to  December  of  2013.
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Materials and Methods
This  was  an  observational  and  cross-sectional  study,  con-
sisting  of  patients  with  a  conﬁrmed  diagnosis  of  pertussis,
performed  in  the  state  of  Paraná,  from  January  2007  to
December  2013.  The  cases  of  pertussis  are  reported  to
the  Notiﬁable  Diseases  Information  System  (Sistema  de
Informac¸ão  de  Agravos  de  Notiﬁcac¸ão  --  SINAN),  in  which
the  notifying  source  completes  a  form  that  provides  data  on
location,  identiﬁcation,  clinical  signs  and  symptoms,  death,
and  vaccination  status  of  patients.
Pertussis  cases  were  conﬁrmed  by:  I.  Clinical  criteria  -  an
individual,  regardless  of  age  and  vaccination  status,  who  had
cough  of  any  kind  for  14  days  or  more  associated  with  two
or  more  of  the  following  signs  and  symptoms:  paroxysmal
cough,  inspiratory  stridor,  and/or  vomiting  after  coughing;
II.  Laboratory  criteria  -  all  individuals  who  met  the  deﬁni-
tion  of  a  suspected  case  of  pertussis  and  have  B.  pertussis
isolated  in  culture  or  identiﬁed  by  RT-PCR;  and  III.  Clinical
epidemiological  criteria  -  all  individuals  who  met  the  deﬁni-
tion  of  a  suspected  case  and  who  had  contact  with  a  case  of
pertussis  conﬁrmed  by  laboratory  testing,  during  the  period
of  communicability.2
All  cases  of  pertussis  conﬁrmed  by  at  least  one  of  the
abovementioned  criteria  were  included  in  the  study.  The
following  epidemiological  and  clinical  variables  were  ana-
lyzed:  age,  sex,  clinical  signs  and  symptoms,  complications,
number  of  deaths,  and  vaccination  status.  This  study  was
approved  by  the  Research  Ethics  Committee  of  Hospital  do
Trabalhador/SESA/PR,  CAAE  16584713.6.0000.5225.
Laboratory  diagnosis
Clinical  samples  (deep  nasopharyngeal  secretion)  of  patients
with  suspected  pertussis  were  referred  to  Lacen-PR  in
Regan-Lowe  (RL)  transport  media  supplemented  with  10%
sheep  blood  and  40  g/mL  cephalexin.  The  samples  were
cultured  in  RL  agar  plates  and  incubated  at  35 ◦C  (±  1)  in  a
humid  environment  for  ten  days.  Suspected  colonies  of  B.
pertussis  were  identiﬁed  through  their  development  after
three  days  of  incubation,  by  demonstrating  Gram-negative
morphology,  catalase  and  oxidase  positivity,  and  compatible
biochemical  identiﬁcation  according  to  published  studies.9
All  isolates  identiﬁed  during  the  study  period  were  stored  in
a  freezer  at  -80 ◦C.
Rep-PCR  Typing
B.  pertussis  isolates  were  typed  by  the  repeated  DNA
sequence  technique  (rep-PCR;  DiversiLab®,  bioMerieux,
France)  to  determine  the  genetic  proximity  between  them.
This  technique  analyzes  speciﬁc  regions  of  the  bacterial
genome  that  may  or  may  not  be  present  in  certain  strains.
When  present,  they  are  ampliﬁed  and  can  be  visualized  by
creating  bands  on  the  virtual  gel  formed  by  the  system.  The
differences  and  similarities  (presence  and/or  intensity  of
bands)  between  isolates  allow  their  classiﬁcation  in  differ-
ent  groups  and  patterns.  Isolates  that  had  ≥  90%  similarity
were  considered  as  belonging  to  the  same  group.  Unique
t
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d
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atterns  (clones)  were  considered  when  isolates  showed
imilarity  ≥  97.0%  to  each  other  and  had  no  different  band.
tatistical  analysis
he  SINAN  system  provides  data  for  the  calculation  of
pidemiological  indicators  using  the  application  TABWIN,
ersion  32  (http://www2.datasus.gov.br/DATASUS/index.
hp?area=060805),  which  generates  reports  from  the  SINAN
ET  Postgres  base  or  the  DBF  base  of  the  NET  or  SINAN
NLINE  versions  (http://dtr2004.saude.gov.br/sinanweb/
ovo/relatorios/descricao.pdf).  To  calculate  the  annual
ncidence,  coefﬁcient  tabulation  was  performed  in  the
ABWIN  format  of  the  number  of  new  cases  each  year
2007-2013),  divided  by  the  state  of  Paraná’s  popula-
ion.  The  DiversiLab  software,  version  1.2.66  (DiversiLab®,
ioMerieux,  France)  analyzed  the  genotyping  results  by
reating  a  proximity  matrix,  using  Pearson’s  correlation
oefﬁcient  to  calculate  distance  matrices  and  create  a  den-
rogram.  The  reports  were  generated  automatically  by  the
ystem.  The  variables  were  described  according  to  their  fre-
uencies.
esults
uring  the  analyzed  period,  3,451  pertussis  cases  were
eported  in  the  state  of  Paraná;  however,  only  1,209  were
onﬁrmed  by  the  above  criteria.  A  considerable  increase  in
he  incidence  of  this  disease  was  observed,  which  ranged
rom  0.15  to  0.76  per  100,000  inhabitants  between  2007  and
010  to  1.7  per  100,000  in  2011,  3.83  per  100,000  in  2012,
nd  4.28  per  100,000  in  2013.  Six  hundred  and  sixty-ﬁve
55%)  patients  were  females.  The  most  affected  age  group
as  the  one  aged  less  than  1  year,  with  816  (67.5%)  cases,
specially  in  infants  younger  than  2  months.
The  clinical  presentation  of  pertussis  may  vary  and  more
han  one  sign/symptom  may  be  present  in  the  same  patient.
he  most  frequent  signs/symptoms  were  paroxysmal  cough,
resent  in  817  (67.5%)  patients,  followed  by  cyanosis  in
63  (63.1%),  vomiting  after  coughing  in  615  (50.8%),  inspi-
atory  stridor  in  504  (41.6%),  and  apnea  in  389  (32.1%).
emperature  ≥  38 ◦C  was  found  in  269  (22.2%)  patients,
nd  temperature  between  37  and  38 ◦C  was  observed  in  389
32.1%;  Fig.  1).  A  signiﬁcant  number  of  patients  required
ospital  admission  and  the  main  complication  was  pneumo-
ia  in  176  (14.5%).  Nineteen  patients  died;  of  them,  11  were
ales,  17  (89.5%)  were  younger  than  2  months  of  age,  one
as  3  months  old,  and  another  was  44  years  old,  with  a
revious  diagnosis  of  tuberculosis.
Almost  half  of  the  patients  with  conﬁrmed  diagnosis  of
ertussis,  592  (49%),  had  already  received  at  least  one  dose
f  DTP  vaccine  and,  among  these,  93  (7.7%)  had  received
hree  doses  and  59  (5%)  had  completed  the  vaccination
chedule  (three  doses  +  two  boosters;  Table  1).
Two  hundred  and  sixteen  (17.9%)  patients  with  pertus-
is  had  a  diagnosis  of  pertussis  conﬁrmed  by  laboratory
esting,  after  B.  pertussis  was  isolated  in  culture.  During
he  reactivation  process,  it  was  observed  that  only  45.8%
n  =  99)  were  viable.  Molecular  typing  (rep-PCR)  was  able  to
etect  and  differentiate  two  major  groups  (G1  and  G2)  and
 different  patterns  (P)  (clones)  among  the  99  isolates  of
336  Torres  RS  et  al.
11(0.9%)Otitis
Encephalopathy
Hospitalization
Temp. ≥38ºC
Temp. <38ºC
Apnea
Stridor
Post-cough vomiting
Cyanosis
Paroxysmal cough
Pneumonia
9(0.7%)
176(14.5%)
706(58.3%)
269(22.2%)
389(32.1%)
389(32.1%)
504(41.6%)
615(50.8%)
763(63.1%)
817(67.5%)
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wigure  1  Signs,  symptoms,  and  complications  associated  to  p
 The  presence  of  any  signs/symptoms/complications  is  not  mu
.  pertussis  analyzed.  The  G1  group  was  the  most  frequent
ith  74  isolates  and  the  G2  group  consisted  of  25  isolates.
he  similarity  between  the  two  groups  was  less  than  62%.
It  was  possible  to  differentiate  ﬁve  different  patterns
P1,  P2,  P3,  P4,  and  P5]  in  the  group  G1,  while  only  three
atterns  [P6,  P7  and  P8]  were  observed  in  G2.  Each  pattern
howed  ≥  97%  similarity  to  the  others,  with  no  different
ands.  The  B.  pertussis  isolate  identiﬁed  in  2007  belonged
o  the  most  frequent  clone  (G1:  P4).  The  isolates  with  the
atterns  [G1:  P2,  P3,  P4,  and  P5]  were  found  to  be  circulat-
ng  in  all  analyzed  years  (Fig.  2).  The  pattern  G2:  P6  was  ﬁrst
etected  in  2009,  and  the  patterns  G2:  P7  and  G2:  P8  cir-
ulated  from  2011,  and  since  then,  have  been  disseminated
n  later  years.  The  G1:  P1  clone  circulated  only  during  the
ear  2012.
iscussion
ertussis  has  resurged  in  the  state  of  Paraná,  increasing  from
6  cases  in  2010  to  178  in  2011.  In  the  subsequent  years,
he  number  of  conﬁrmed  cases  has  continued  to  increase,
ith  400  in  2012  and  447  in  2013.  This  may  be  associated
ith  the  presence  of  multiple  circulating  clones  of  B.  per-
ussis.
r
f
f
s
Table  1  Conﬁrmed  cases  of  pertussis  by  age  range  and  number  of
during the  period  of  2007-2013.
Age  range  Missing  info  1  Dose  2  Doses  3  D
<  1  year  98  233  86  40
1-4 y  26  11  2  49
5-9 y  19  1  0  0
10-14 y  10  0  0  1
15-19 y  11  0  0  0
20-34 y  31  0  0  2
35-49 y  22  0  0  0
50-64 y  6  0  0  1
65-79 y  5  0  0  0
Total 228  245  88  93
Missing info, Missing information; 3 + B, three doses plus one booster d
vaccinated.ts  with  pertussis.*
y  exclusive.
Brazil  started  the  systematic  control  of  pertussis  in
983,  with  the  inclusion  of  the  DTP  vaccine  in  children’s
asic  vaccine  schedule,  around  the  time  when  developed
ountries  indicated  the  ﬁrst  signs  of  disease  resurgence.10,11
n  1990,  vaccination  coverage  increased  to  approximately
0%  and  the  incidence  of  the  disease  decreased  from  30
o  10.6/100,000  inhabitants.  In  the  last  decade,  the  inci-
ence  of  pertussis  in  Brazil  remained  stable,  ranging  from
.72/100,000  inhabitants  in  2004  to  0.32/100,000  inhabi-
ants  in  2010.  In  2011,  there  was  a  sudden  increase  in  the
umber  of  conﬁrmed  cases  in  relation  to  the  previous  ﬁve
ears,  increasing  the  incidence  to  1.2/100,000  inhabitants,
ven  though  high  vaccination  coverage  was  maintained.12
The  classic  symptoms  of  pertussis  are  prolonged  (‘‘100-
ay  cough’’)  and  paroxysmal  coughing,  accompanied  by
oisy  breathing  (inspiratory  stridor).4 Cyanosis  was  a  very
ommon  ﬁnding  in  patients  of  the  present  study,  in  addi-
ion  to  the  presence  of  the  classic  symptoms.  Nicolai  et  al.
eported  that  paroxysmal  cough  is  a  highly  speciﬁc  symp-
om  for  the  diagnosis  of  pertussis,  present  in  63.2%  of  cases,
hereas  not  found  in  patients  with  bronchiolitis  caused  by
espiratory  syncytial  virus  (RSV).  The  rate  of  cyanosis  (52.6%)
ound  in  patients  with  pertussis  was  also  higher  than  that
ound  in  patients  with  RSV  infection  (10.5%),  with  statistical
igniﬁcance  (p  = 0.006).13 In  the  series  evaluated  by  Bayhan
 diphtheria-tetanus-pertussis  (DTP)  vaccine  doses  in  the  state
oses  3  +  B  3  +  2  B  Not  Vacc.  Total
 0  0  359  816
 61  12  2  163
 13  34  1  68
 20  12  4  47
 4  0  1  16
 9  1  8  51
 0  0  10  32
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Figure  2  B.  pertussis  groups  and  patterns  identiﬁed  in  the  state  of  Paraná  between  2007-2013.
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et  al.,  39.3%  of  patients  with  pertussis  had  inspiratory  stridor
and  87.1%  had  cyanosis.14
Pneumonia  was  the  main  complication  found  in  the
patients  studied  herein.  This  complication  is  the  most
common  cause  of  death  related  to  pertussis.  In  the
United  States  and  Canada,  pneumonia  was  observed  in
5.2%  and  9.4%  of  cases,  respectively.15,16 B.  pertussis
triggers  a  cascade  of  inﬂammatory  events  that  includes
acute  pulmonary  vasoconstriction  and  increased  leukocyte
circulation,  which  affects  pulmonary  blood  circulation,
exacerbates  hypoxemia,  and  creates  a  vicious  cycle  of  pul-
monary  hypertension.17
In  this  study,  most  deaths  occurred  during  the  last  three
years  of  the  study,  and  in  children  younger  than  2  months
of  age.  According  to  SINAN  data,  a  total  of  15,428  cases  of
pertussis  were  reported  in  Brazil  in  2011,  of  which  2,248
were  conﬁrmed,  with  56  deaths  and  mortality  of  2.5%.
The  number  of  cases  continued  to  increase  in  2012,  with
5,416  conﬁrmed  cases,  84  deaths  associated  with  the  dis-
ease,  and  mortality  of  1.6%.  In  2013,  the  state  of  Paraná
accounted  for  10%  of  deaths  recorded  in  Brazil.12 In  England,
between  2001  and  2011,  a  total  of  48  deaths  were  recorded
due  to  the  disease  in  children  younger  than  1  year  of  age;
of  these,  41  (85.41%)  were  younger  than  66  days  of  life.18 In
the  US  in  2012,  a  total  of  48,277  cases  were  reported  and
there  were  18  (0.04%)  deaths,  which  is  the  highest  recorded
number  of  cases  of  the  disease  in  the  last  60  years  in  that
country.19 It  is  observed  that  the  disease  lethality  in  Brazil
exceeded  40  times  that  found  in  the  USA.
The  currently  available  vaccines  are  considered  safe  and
immunogenic;  however,  they  provide  protection  with  an
approximate  effectiveness  of  46%  after  the  1st dose,  79.6%
after  the  2nd dose,  91.7%  after  the  3rd dose,  and  96.4%  after
the  4th dose,  lasting  about  10  years.20,21 In  the  present  study,
59  (5%)  children  had  completed  the  vaccination  schedule
(three  doses  +  two  boosters),  but  still  developed  the  disease.
The  rep-PCR  technique  allowed  the  identiﬁcation  of
eight  B.  pertussis  clones  (P1  -  P8)  circulating  in  the
d
t
e
Bgerprinting  system.  G,  Group  (1  and  2).  P,  Pattern  (P1,  P2,  P3,
tate  of  Paraná.  It  is  possible  that  the  current  clones
ave  different  antigenic  variations  than  those  found  in
he  clones  circulating  in  the  pre-immunization  period,22,23
r  they  might  even  be  different  from  the  strain  used
n  the  vaccine  production.  Therefore,  the  vaccine  would
ot  show  the  expected  effectiveness  against  all  circu-
ating  strains.  It  has  been  suggested  that  B.  pertussis
dapted  due  to  selective  pressure  exerted  by  the  vaccine
uring  the  last  60  years,  expressing  pertussis  toxin,  per-
actin,  and  ﬁmbria  differently  from  those  found  in  the
accine  strain.  These  modiﬁcations  may  explain  in  part
he  decrease  in  vaccine  efﬁcacy,  prompting  the  hypothesis
hat  vaccine-induced  reduced  immunity  may  be  respon-
ible  for  the  increased  number  of  cases  of  the  disease
orldwide.24
Another  issue  is  that  the  current  vaccination  strategies,
ocusing  only  on  children,  appear  insufﬁcient  to  prevent
eath  in  young  infants.  Thus,  new  strategies  must  be  ana-
yzed  to  include  vaccination  in  newborns,  adolescents,
he  elderly,  health  care  workers,  professionals  working
ith  children  in  nurseries  and  kindergartens,  and  pregnant
omen.20,25,26 While  it  is  not  possible  to  provide  booster
oses  for  the  entire  population,  it  is  a  priority  to  vacci-
ate  individuals  who  have  direct  contact  with  young  infants,
specially  mothers,  as  well  as  to  maintain  high  vaccine  cov-
rage  in  children.25
This  study  has  some  limitations.  It  is  possible  that  the
umber  of  pertussis  cases  was  underreported.  The  lack
f  familiarity  with  the  pertussis  diagnosis,  explained  by
he  long  period  during  which  the  disease  remained  under
pidemiological  control,  may  have  inﬂuenced  the  disease
ncidence  rates.  Another  factor  that  might  have  contributed
s  that  some  patients  have  milder  symptoms,  which  are  sim-
lar  to  viral  infections,  making  it  difﬁcult  to  suspect  and
iagnose  the  disease.  In  these  cases,  it  is  important  to  iden-
ify  the  infection  etiology;  however,  the  conﬁrmation  of  viral
tiology  does  not  rule  out  the  possibility  of  coinfection  with
.  pertussis.27
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The  authors  conclude  that  pertussis  is  a  re-emerging
isease  in  this  state,  with  non-immunized  infants  repre-
enting  the  most  often-affected  age  range.  However,  it  was
bserved  that  some  children  developed  the  disease  despite
aving  been  fully  vaccinated.  Advanced  studies  on  cell  and
olecular  biology  should  be  encouraged  to  recognize  anti-
enic  changes  in  different  clones  of  B.  pertussis  currently
irculating  and  offer  new,  more  effective,  and  more  pro-
ective  vaccines  to  the  population.  The  resurgence  of  the
isease  also  requires  urgent  changes  in  the  planning  of  new
accination  strategies  aiming  to  reduce  the  risk  of  acquiring
he  disease  and  infant  morbimortality.
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